Skip to main content

Table 1 Clinical summary of the 10 patients studied and their response to treatment

From: A pilot study of IL-1 inhibition by anakinra in acute gout

Patient Clinical presentation Affected joints Serum uric acid (normal range, 160–390 μmol/l) Serum creatinine (normal range, 44–80 μmol/l) Hypouricemic treatment Effect of anakinra (hours) Patient assessment of improvement in pain (%)
Case 1 (female, 72 years old) Chronic tophaceous gout, renal stones Fingers, toes 637 79 Uricase 36 70
Case 2 (male, 70 years old) Chronic tophaceous gout Ankle, toes 564 202 Allopurinol 24 90
Case 3 (male, 72 years old) Acute gout Knee, ankle, foot 482 121 Allopurinol 24 90
Case 4 (male, 51 years old) Acute gout Ankle, toe 396 84 Allopurinol 24 100
Case 5 (male, 40 years old) Acute gout Ankle, toe 322 113 Allopurinol 36 100
Case 6 (female, 72 years old) Acute gout Feet, toe 572 72 None 36 80
Case 7 (male, 76 years old) Acute gout Ankle, foot 338 79 None 36 100
Case 8 (male, 70 years old) Acute gout Wrist, elbow, hand 779 406 None 48 50
Case 9 (male, 53 years old) Chronic tophaceous gout Elbow, finger, foot, ankle 660 84 Allopurinol 48 50
Case 10 (male, 38 years old) Acute gout Wrist, finger 540 84 None 24 60